Introduction
Congenital heart disease (COHD) is a heart condition resulting from an abnormality in heart structure or function that is present at birth. Some common congenital heart defects include Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Left Atrial Appendage (LAA) and Patent Ductus Arteriosus (PDA). Ventricular Septal Defects (VSD) is the most common type of congenital heart defects in newborns. The Centre for Disease and Control (CDC) estimates that about 42 out of every 10,000 babies are born with VSD in the United States.

Most congenital heart diseases are diagnosed in babies (aged under a year), 30% in children (aged 1-15 years), and 10% in adulthood (16 years and over). The increasing number of addressable patients for congenital heart defects in the U.S, Europe and Japan is a potential opportunity for this market. In addition, the mortality rate attributable to congenital defects has been declining over the last few years.

Rise in survival rates of COHD patients till adulthood, evolution of new diagnostic techniques, increasing consumer income and rising number of cardiologists and medical practitioners are the main factors that will be driving the market in future.

The congenital heart defect market is characterized by few competitors due to high entry barriers. AGA Medical is the market leader in the structural heart repair market. The other major players include NMT Medical, St. Jude medical, GORE Medical, Occlutech and Coherex.

Scope
The current report analyzes the market size and segmentation of the congenital heart diseases market. The various drivers, opportunities and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

Reasons to Purchase
Provides input for strategic business planning
Insights on competitive positioning
Identifies business opportunities & challenges
Analyzes market growth and future trends

Report Highlights

[Studien Infos ausblenden]

TABLE OF CONTENTS
1. Cardiovascular Diseases

Deaths from Cardiovascular Diseases (CVD)
CVD Deaths Breakdown
CVD Prevalence

2. Congenital Heart Diseases Overview

2.1 Causes of Congenital Heart Defects
2.2 Common Congenital Defects
2.2.1 Structural Heart Defects

3. Global Congenital Heart Disease Market Size

Market Opportunity
Annual Cases of Congenital Heart Diseases

4. Market Segmentation of Congenital Heart Diseases

4.1 Atrial Septal Defect (ASD)
4.2 Ventricular Septal Defect (VSD)
4.3 Patent Foramen Ovale (PFO)
4.4 Left Atrial Appendage (LAA)
4.5 Patent Ductus Arteriosus (PDA)

5. Market Trends

5.1 Mortality Trend
5.2 Prevalence Rates of Congenital Cardiovascular Defects
5.3 Evolution of Diagnostic Methods
5.4 Risks Associated With Maternal Illness

6. Market Drivers

6.1 Rise in Survival of COHD Patients till Adulthood
6.2 Increasing Congenital Heart Defect Cases
6.3 New Diagnostic Techniques
6.4 Rising Consumer Income

7. Challenges

7.1 High Treatment Costs
7.2 Less Number of Medical Practitioners

8. Competitive Landscape

9. Company Profiles

9.1 AGA Medical

Business Description
Business Strategies
Organic Growth through New Product Introductions
Capitalize on the PFO Market Opportunity
Expand and Commercialize Research and Development Pipeline
Continue to Strengthen Global Distribution

9.2 NMT Medical

Business Description
Business Strategies
Continue to Strengthen Global Distribution
Expand Market Share in High Growth Regions

9.3 St. Jude Medical

Business Description
Business Strategies
Acquisition Strategy
Focus on Cardiovascular Segment
[Inhaltsverzeichnis ausblenden]

Age adjusted Prevalence Estimates (2008)
Occurrence of Common Congenital Heart Defects
Market Potential for Structural Heart Defects (2009)
Estimated Global Market Opportunity for ASD Closure Devices (2008)
Cryptogenic Stroke PFO Closure Annual Market Opportunity (2009)
Migraine PFO Closure Annual Market Opportunity (2009)
Left Atrial Appendage Occlusion Annual Market Opportunity (2009)
Mortality from Congenital Heart Defects, U.S (2006)
Prevalence rates for Congenital Heart Defects and Associated Clinical Characteristics
Exposure Associated with Definitive or Possible Risk of Offspring with COHD (2007)
Estimated Direct and Indirect Costs for Various Treatments in the U.S (2010)
Current Competitive Landscape for Structural Heart Repair (2009)
Deaths from Cardiovascular Diseases in the U.S
Breakdown of Deaths from CVD in the U.S
Prevalence of CVD in Adults by Age and Sex, U.S
Diagnosis of Congenital Heart Disease by Age (2008)
Worldwide Market Opportunity for Congenital Heart Diseases (2005E-2012E)
Estimated Global annual Cases of Congenital Heart Defects (2005E-2012E)
Estimated Worldwide Market Opportunity for ASD (2005E-2010E)
Estimated Worldwide Market Opportunity for VSD (2005E-2010E)
Total Annual VSD Interventions Worldwide (2005E-2012E)
Estimated Worldwide Market Opportunity for PFO (2008E-2015E)
Estimated Total PFO Treatable Population (2008E-2015E)
Estimated Worldwide Market Opportunity for PDA (2005E-2011E)
Hospital Discharge Mortality Rate in the U.S (2004-2007)
Patients Reaching Adulthood with Congenital Heart Disease Globally (1970-2010E)
Estimated Worldwide Population with Congenital Heart Disease (2005E-2012E)
World Gross National Income Per Capita by Region (2001-2008)
Revenue of AGA Medical (2005 -2009)
Revenue of NMT Medical (2005 -2009)
Revenue of St. Jude Medical (2005 -2009)
[Tabellenverzeichnis ausblenden]